THE DENTAL CLINICS OF NORTH AMERICA SAUNDERS Dent Clin N Am 49 (2005) 923-939 Cumulative Index 2005 Note: Page numbers of article titles are in boldface type. A Antibiotics, 419-420 Acanthosis nigricans, familial, 251 in periodontal disease, 618-622 Adhesive restorations, cavity preparation Antibodies/infectious diseases, oral-based design considerations for, 889-89] diagnostic tests for, 454 Adhesive systems, self-etch, 895-897 Antidepressants, tricyclic, in trigeminal total-etch, 892-895 neuropathy, 352 Adhesives, glass-ionomer, 897 Antihypertensive agents, 416 Advance health care directives, 405-406 Anti-inflammatory agents, 421 in oral mucositis, 177-178 Aging, cognitive impairments and, 392-395 Antimicrobials, in oral mucositis, memory and, 391-392 178-179 locally applied, 618-622 Air abrasion, for cavity preparation in systemic, 622-623 caries, 874-876 Antioxidants, in oral mucositis, 179-180 Alendronate, in osteoporosis, 470-471 Antiphospholipid syndrome, in lupus Allogenic bone grafts, for periodontal erythematosus, 137 regeneration, 640-641 Antiseptics, periodontal disease and, Alloplasts, for periodontal regeneration, 616-618 642-643 Aphthous stomatitis, recurrent, 31-47 Alzheimer’s Association’s 10 Warning allergic factors in, 37-38 Signs, 400-402 characteristics of, 32, 33 Alzheimer’s disease, as cause of dementia, clinical manifestations and 398-403 pathogenesis of, 39-40 criteria for diagnosing, 402 epidemiology of, 32-33 etiologic factors in, 34-39 Amalgam, dental, 320 hereditary and genetic factors in, 37 Amalgam preparations, class I, and immunologic factors in, 38-39 extension for prevention, 816-817 management of, 40-42 Amalgam tattoo, 197-198 medical disorders associated with, 36-37 Amifostine, 317 microbial factors in, 35-36 Amphotericin B, 62 nutritional factors in, 39 psychologic stress and, 39 Anabolic agents, in osteoporosis, 473 Arestin, 621-622 Analgesics, 420-421 Argyrosis, focal, 197-198 Anesthetics. local, 422-423 Arthritis, polyjoint, in elderly, 327 Angiotensin-converting enzyme inhibitors, in temporomandivular joint, 414-415 pharmacologic treatment Ankyloglossia, || of, 337-338, 339 0011-8532/05/$ - see front matter © 2005 Elsevier Inc. All rights reserved. doi:10.1616/S001 1-8532(05)00070-4 dental.theclinics.com 924 CUMULATIVE INDEX Arthritis (continued) freeze-dried, for periodontal social and economic impact of, regeneration, 641 327-328 Bone grafts, allogenic, in periodontal Arthrocentesis-based lavage, in regeneration, 640-641 osteoarthritis of temporomandibular autogenous, in periodontal joint, 335-336, 339 regeneration, 640 human mineralized, for periodontal Aspergillosis, 57 regeneration, 642 Atherosclerosis, periodontal disease replacement, for periodontal associated with, 535-537 regeneration, 640-642 Atraumatic restorative treatment, 820—821 Bone matrix, demineralized, Grafton, for periodontal regeneration, 642 Atridox, 620-621 Bone mineral density, hormone replacement Autofluorescence, enamel, 755—756 therapy and, 468-469 Autogenous bone grafts, for periodontal low femur, prevalence of, 464 regeneration, 640 measurement of, using dual energy x-ray absorptiometry (DEXA), Autoimmune diseases, saliva and, 311—314 465-466 Azoles, 59 reduced, 463 Bone morphogenetic proteins, for periodontal regeneration, 645 B Bone-specific markers, of tissue destruction, B cells, and periodontitis, 506 for periodontal diagnosis, 557—558 Bacterial cultures, in periodontal disease, Bruxism, 344-345 679-680 Bullous pemphigoid, juvenile, 248 Behcet’s syndrome, 36, 255 Burning mouth symptoms, 354—-356 Biofilm-associated bacteria, antimicrobial resistance and, 494 Burning tongue, 354 bacterial antigens and virulence factors Burs, self-limiting polymer, for removal of in, 495 hidden caries, 880-883 cell-cell communication in, 494 site-specific, for preparation for extracellular proteolytic enzymes and, preventive resin restorations, 497 876-883 fimbriae in, 496-497 gene transfer in, 494 heat shock proteins and, 495-496 C lipopolysaccharide, 495 Caffeine consumption, and osteoporosis, regulation of gene expression in, 494 468 Biomarkers, host response and Calcitonin, in osteoporosis, 472 inflammatory mediators as, 555-557 Calcium, in body, 602, 605 Biotin, 600 intake in aging, 467 Biphosphates, in osteoporosis, 470-471, 475 supplemental, to prevent bone loss, 469, 470 Bisphosphonates, in periodontal disease, 685-686 Calcium channel blockers. 415 Blastomycosis, 58 Cancer, oral, 369 anatomic sites of, 145 Blepharospasm, 344 clinical examination in, 148—149 delay in diagnosis of, 149-150 Bonding and curing, considerations for, for etiology of, and risk factors of, hidden and incipient caries, 889-904 146-147 Bone allograft, demineralized treeze-dried, genomics and, 154-155 for periodontal regeneration, imaging in, 159 641-642 immune system and, 147 CUMULATIVE INDEX 925 incidence of, 144 carbohydrate intake and, 705-706 leukoplakia, and squamous cell cavity preparation design and, for carcinoma, 143-165 adhesive restorations, 889-891] molecular progression of, 153 cavity preparation in, air abrasion monoclonal antibodies for for, 874-876 detection of, 158—159 and restoration, 872-874 nutrition and, 148 cavity size and, shrinkage and stress precancerous classification of, of restoration and, 898 153-154 clinical diagnosis of, uncertainties in, saliva-based diagnostics for, 455 850-851 signs and symptoms of, 150-152 commencing at contact area, 719 stage at diagnosis and survival coronal, 294-295, 297, 302 of, 145-146 defining, classifying, and placing in tobacco use and, 147-148 perspective, 701-723 viruses in development of, 148 demineralization of tooth surface in, 702, 707-708, 709 Candida infections, oral, 50 detection of, and monitoring of, diagnosis of, 55-56 912-914 Candida lesions, group I, classification of, DIAGNOdent for, 745-747, 50-54 802-803 lesions asociated with, 53-54 DIFOTI diagnostic tool for, 803 digital imaging for, 799-800 Candidiasis, erythematous, 51 and imaging process for, host factors associated with, 54—55 744-745 hyperplastic, 52-53 methods of, 798-799 leukoplakia, and erythroplasia, 156 new technologies for, 868-869 pseudomembranous, 50-5] quantitative light-induced Capsaicin cream, in osteoarthritis of fluorescence for, 800-802 temporomandibular joint, 334 radiographic examination for, 797-798 Carbamazepine, in trigeminal neuralgia, 350 radiology for, 739-740 Carbohydrates, intake of, caries and, techniques of, 740, 743-744 705-706 traditional methods of, 754 role in nutrition, 596-597 visual and tactile examination for, 795-797 Carcinogenesis, oral, 152-153 diagnosis of, detector dyes in, 854-856 new technology for, 833-835 Cardiovascular disease(s), and earliest stages of, 701 periodontitis, in elderly, 287 early imaging and monitoring of, with in lupus erythematosus, 136 near-infrared light, 771-793 periodontal disease associated with, etiology of, 293-294 535-537 flow of saliva and, 309-310 Cardiovascular drugs, 414-416 fluoride exposure and, 706-707 gingival margin location, 858-859 Care staff, long-term, 380-381 hidden, and incipient, bonding and Caregivers, informal, 379-380 curing considerations for, 889-904 Caries, active, and arrested, discrimination dental hygiene management of, 835 options for, 804-811 early detection of, quantitative management of, dental laser fluorescence for, hygiene participation 765-766 in, 795-813 alternative management stategies for, material for restoring, 303-304 900-90] and restorative considerations, in dry nonsurgical treatment of, mouth, 319-322 905-921 as multifactorial disease, 849-850 prevention intervention association with diet, in preschool therapeutic plan for, children, 725-737 806-81! Black classification of, 716-717 926 CUMULATIVE INDEX Caries (continued) sizes of, 718-719 detection of, quantitative laser prevalence of, 294-295 fluorescence for, 766 in nursing home elderly, 295, 296 diagnosis of, 867-868 prevention of, 299-302 radiography in, 833 process of, 726-727 removal with self-limiting quantitative light fluorescence polymer bur, 880-883 for, 753-770 in cervical region, 720 understanding of, 804 in older adults, 293-308, 431-433 proximal, management of, 852 incidence of, 295-296, 753, 833 re-restoration cycle and, 851 incipient, and hidden, bonding and recurrent, minimizing of, 829-830 curing considerations for, restoration in, design and preparation 889-904 of, 720-721 material for restoring, risk to patient, and salivary flow, 900-901 911-912 nonsurgical treatment of, assessment of, chart for, 910 905-921 classification of, 908-909 contemporary treatment of, and establishment of, 906-911 conservative techniques in, re-evaluation of, 912 867-887 root surface, 295, 297, 302-303 instrumentation for, 871 significance of, risk factors for, magnification for, 872 298-299 restorative materials for, to health and economics, 871-872 296-298 infection due to, treatment of, 905 sites of, classification of, 717-718 initiation and progression of, dietary transmission of, 726-727 factors in, 727-729 treatment of, 870-871 into dentin, 713-715 early, evidence for and against, management of, 302-303 835-838 future directions in, 304-305 risk analysis and, 835, 869-870 medical management of, New York types of food products and, 729-730 University College of Dentistry, untreated, in elderly, 367 915-916 “white spot” lesion and, 726, 754 ozone treatment for, 917-918 Cevimeline, 318, 319 patient communication for, 917 near-infrared imaging and Chewing stick, 608 transillumination of, compared, 785-790 Chickenpox, in children, 245-246 noncavitated, monitoring of, emerging Children, caries association with diet in. technologies for, 913-914 725-737 occlusal, diagnosis of, 852-854 chickenpox in, 245-246 detector dyes in, 855-856 soft tissue lesions m, 241-258 operative intervention thresholds for, with HIV disease, orofacial disorders 851-854 in, 259-271 Operative management strategies in, conservative, 847-865 Chlorhexidine, 585, 617 for proximal only for caries control, 301 restoration, 857-86] Chromium, functions of, 604 for proximal tunnel restoration, 856-857 Cimetidine, 417 scientific rationale for, Clonazepam, in burning mouth symptoms, 849-85] 355 minimally invasive, 847-849 oral-based diagnostic tests for, Co-jet air abrasion system, 901] 452-453 Coenzyme Qj,, 607 patients at risk for, identification of, 804-806 Cognitive changes, identification of, n pit and fissure, incipient and hidden, dental office, 390-39] clinical diagnosis of, 831-833 in elderly, recognition of, 395-396 CUMULATIVE INDEX 9?7 Cognitive function, aging, and ethical Dental hygienist, in management of decisions, 389-410 incipient and hidden caries, 795-813 hints and suggestions for management options for, in hidden addressing, 406-408 or incipient caries, 804-811 loss of, with age, 391-392 Dental implants, osteoporosis and, 477-478 Cognitive impairment(s), and aging, Dental office, identification of cognitive 392-395 changine, s 390-391 miid, 396-398 Dental plaque. See Plaque. Collagen, type 1, pyridinoline cross-linked carboxyterminal telopeptide of, Dental use services, 366-367 558-560 Dentin, and enamel, adhesion to, Compomers, 321 contemporary principles of, 891-897 and sound enamel, optical properties Composite, curing, stress relief in, 898-899 of, in near-infrared light, 775-776 Copper, sources of, 604 caries into, 713-715 Corticosteroid injections, in osteoarthritis Dentists, medications prescribed by, of temporomandibular joint, 333, 339 419-423 Crohn’s disease, 36 Dentures, fibrous hyperplasia induced by, and orofacial granulomatosis, 215-216 235-236 clinical findings in, 214-216 Dermatitis herpetiform, juvenile, 249-250 diagnostic tests in, 216 gene mutations in, 214 Detector dyes, in diagnosis of caries, treatment and prognosis in, 216-217 854-856 Cryotherapy, in oral mucositis, 180 Diabetes mellitus, and periodontitis, in elderly, 287-288 Cryptococcosis, 57 periodontitis in, treatment of, 546 Cyst(s), lateral periodontal, 234 risk of periodontitis in, 545 pediatric oral, 254-255 types of, 544 Cytomegalovirus, 24-25 DIAGNOdent device, 745-747, 802-803, 855-856. 881, 913-914 Diet, caries association with, in preschool D children, 725-737 Decision-making capacity, assessment of, caries initiation and progression and, 404-405 727-729 Dementia, 392-395 Dietary guidelines, oral health, for children, symptoms of, observed by dental team, | to 2 years old, 733-734 403 2 to 5 years old, 734-735 birth to | year old, 732-733 Demineralized freeze-dried bone allograft, for expectant mothers and for periodontal regeneration, 641-642 preschool children, 735 Dental and medical care, demand for, in prenatal period, 731-732 449-452 DIFOTI diagnostic tool, 747-749, 772, for old-old, 451 803, 834, 914 for oldest-old, 450-451 for young-old, 451-452 Digital imaging fiberoptic transillumination. See DIFOTI Dental care, versus medical care, subsidized, diagnostic tool. 366 Digoxin, 416 Dental caries. See Caries. Diuretics, 415 Dental disability, adaptations to cope with, 436-438 Drug-induced pigmentations, 198 Dental disease, educational programs to Drug monitoring, therapeutic, oral prevent, 436-438 diagnostics for, 454-455 928 CUMULATIVE INDEX Drug reactions, lichenoid, 86 Enamel, and dentin, adhesion to, contemporary principles of, 891-897 Drugs. See Medications. demineralized, optical property Dry mouth, restorative treatment in, changes in, 776-778 319-322 penetration of, by near-infrared light, 772, 773 Durable power of attorney for health care, sound, and dentin, optical properties 405 of, in near-infrared light, Dysesthesia, occlusal, 356-359 775-776 explanations for, 357—358 Enamel autofluorescence, 755-756 treatment of, 358-359 Enamel fluorescence, 755-756 Dysmorphophobia, 358 Enamel lesion, early, 710-713, 714, 715 Dysplasia, oral, and malignant transformation, 152 Enamel matrix derivative(s), for peridontal Minnesota dentist’s follow-up of, regeneration, 646 151 in periodontal disease, 684-685 Dystonia, 344, 345 Endocrine agents, 418-419 Endocrine disorders, pigmented lesions related to, 199-200 E Ecchymosis, 190 Enzymatic assays, in periodontal disease, 680 Echinocandins, 63 Ephelis, 187-188 Edentulousness, in elderly, 282-283 Epidermolysis bullosa. hereditary, 249 Elderly, at risk for periodontitis and systemic diseases, 279-292 Epstein-Barr virus, 25—26 caries and, 431-433 Epulis, congenital, 252 caring for, effective communication in, 383-388 Erythema migrans, 7-8 health care team and, Erythema multiforme, 67—76 378-379 classification of, 67-68 interaction with health team clinical presentation of, 69-72 members in, 377-388 diagnosis of, 72 cognitive changes in, recognition of, etiology of, 68 395-396 features of, 67 definition of, 279 treatment of, 73-74 emergency and diagnostic services for, 431 Erythroleukoplakia, 348, 352, 363 frail, oral health status of, 430-431 Erythroplasia, 155 gingivitis and periodontal disease in, with ulceration, 155 434 issues of, underserved in United States. Estrogen-receptor modulators, selective, in burdens of oral and medical osteoporosis, 471-472 health care, 363-376 Ethical decisions, cognitive function, and medication use and prescribing aging, 389-410 considerations for, 411-427 hints and suggestions for oral diagnosis for, 445-461 addressing, 406-408 oral hygiene and, 434-435 oral implants for, 433-434 Etidronate, in osteoporosis, 471 prevention and treatment strategies for, 431-435 Exercises, in osteoarthritis of prosthodontics for, 433 temporomandibular joint, 333 restorative treatment for, 433 F Elderly Americans, and oral health status, 366-368 Facial pain, of neurovascular origin, 349 rationale for targeting, 364-365 of vascular origin, 347-349 CUMULATIVE INDEX 929 related to chronic trigeminal Freeze-dried bone allograft, for periodontal neuropathy, 351-353 regeneration, 641 related to muscle pain, 345-347 Fungal infections, oral, 49-65 related to postherpetic neuralgia, deep, 56-58 353-354 diagnosis of, 58—59 related to trigeminal neuralgia, superficial, 49-50 349-351 treatment of, 59-63 Fiberoptic transillumination, 772 digital imaging. See DIFOTI diagnostic tool. G Fibroma, irritation, 223—224 Gastrointestinal agents, 417 peripheral ossifying, 231-232 Gene polymorphisms, 527 traumatic, 223—224 Fibromatosis, gingival, 228-229 Geographic tongue, 7-8 Fibromyalgia syndrome, 345-346 Geotrichosis, 57—58 behavioral treatments in, 347 Geriatric populations. See Elderly. medications for, 346 Giant cell arteritis, 347—348 Fibrous hyperplasia, denture-induced, 235-236 Gingiva, crevicular fluid sampling of, diagnostic test based on, 563 Fine-needle aspiration, 158 recession of, 281-282, 523-524 Fissured tongue, 10 retrocuspid papilla of, 3 Flaps, coronally positioned, for periodontal Gingival overgrowth, generalized, 232-234 regeneration, 639-640 Gingivitis, 518, 520 Florida Dental Care Study, 370 acute necrotizing ulcerative, in children, 241-242 Fluorescence, enamel, 755-756 bacteria associated with, 499 laser. See Laser fluorescence. development of, plaque accumulation light, quantitative, for monitoring of and, 501 caries process, 753-770 in older adults, 434 light-induced quantitative, for necrotizing ulcerative, 500 detection of caries, 800-802 Gingivostomatitis, primary herpetic, in Fluoride, dietary, 595 children, 243, 244 exposure to, caries and, 706-707 Glass ionomers, conventional, 320 resin-modified, 320, 321 functions of, 604, 753 in osteoporosis, 472-473 Glass-ionomers, adhesives for, 897 Fluoride dentifrice, to prevent caries, Glossitis, benign migratory, 7-8 299-300 Glossopyrosis, 354 Fluoride gels, to prevent caries, 300-301 Grafton demineralized bone matrix, for Fluoride-releasing restorative materials, periodontal regeneration, 642 321, 322 Granuloma, peripheral giant cell, 230-231 Fluoride rinses, to prevent caries, 300 pyogenic, 229-230, 252 Fluoride varnishes, to prevent caries, 301 Granulomatosis, orofacial, causes of, 217 Folate, 600 clinical findings in, 217-218 Crohn's disease and, 216-217 Fordyce granules, of labial and buccal diagnostic tests in, 218 mucosa, 4, 5 treatment and prognosis in, 219 Forgetfulness, benign senescent, 396-398 Granulomatous diseases, immune-mediated granulomatous inflammation and, FOTI technology, 834 205-206 Frailty, and long-term care recipients, 430 in foreign body reactions, 204-205 930 CUMULATIVE INDEX Granulomatous (continued ) virologic tests in, 21 of oral tissues, 203—221 Herpes simplex virus, 16 common, 204 Herpes zoster, 22-24 Growth factors/cytokines, for periodontal regeneration, 645-646 Herpetic infections, oral (HSV 1-8), 15-29 Guided cell repopulation/guided tissue Histamine-2 receptor antagonists, 417 regeneration, for periodontal regeneration, 644-645, 647-652 Histoplasmosis, 57 HIV disease, pediatric, classification system for, 260-261, 263, 264 H factors influencing, 259 Hairy tongue, 9-10 incidence of, 259-260 Hand-foot-and-mouth disease, in children, oral lesions in, classification of, 245 261-263, 265 epidemiology of, 264-268 Head and neck, cancer of, incidence of, treatment modalities for, 143, 144 268-269 TMN staging of, 146 orofacial disorders in, 259-271 manifestations of lupus erythematosus orofacial manifestations of, 261 in, 137-138 Hormone replacement therapy, bone Health care, disparities in, history of, mineral density and, 468-469 365-366 poor access to, risk factors for, 363 Human herpes virus 6, 26 Health care information, essential, 381—383 Human herpes virus 7, 26 Health care proxies, 405 Human herpes virus 8, 27 Health record, for older adults, basic Human mineralized bone graft, for elements of, 381—382 periodontal regeneration, 642 decisional support and advanced Hyaluronic acid injections, in osteoarthritis directives of, 383 of temporomandibular joint, 334 functional assessment in, 382-383 social history in, 382 Hydroxyapatite, 707 Heart attack, periodontal disease and, 536 Hypertension, salivary hypofunction, 315 Heavy-metal pigmentation, 198 Heck’s disease, in children, 247 Ibandronate, in osteoporosis, 471 Hemangioma(s), 195-196 congenital, intraoral, 252 Imidazoles, 59-61 Hematologic disorders, in lupus Immune system, perdiodontitis, in elderly, erythematosus, 137 284 Hematoma, 190 Immunoassays, in periodontal disease, 680 Hemochromatosis, 199-200 Incisive papilla cyst, 254-255 Herbal supplements, periodontal disease Infantile febrile mucocutaneous lymph node prevention and, 607-608 syndrome, acute, 250 Herpangina, in children, 244, 245 Infection(s), bacterial, of pediatric soft tissue, 241 Herpes simplex infection(s), cytology fungal. See Fungal infections. smears in, 21 in lupus erythematosus, 136-137 differential diagnosis of, 20-21 initiating periodontal disease, 611-612 immunomorphologic tests in, 21 related to caries, treatment of, 905 primary, 16-17 recurrent, 17-20 Inflammation, leading to tissue destruction, serologic tests in, 21—22 665-666 CUMULATIVE INDEX 93] Informed consent, cognitive impairment chemoprevention of, 160 . and, 403-404 cytology and brush biopsy of, 157-158 diagnosis and management of, Informed decisions, ability to make, factors 156-157 compromising, 404 follow-up examination in, 160 Instruments, cavity preparation, effects on oral cancer, and squamous cell bonding, 899-900 carcinoma, 143-165 for use in incipient caries, 871 proliferative verrucous, 155—156 stained with toluidine blue, 158, 159 Interdental cleaning, 581—5&2 treatment of, 160-161 Interleukin-1, in periodontal disease, 507 Levothyroxine, 419 Interleukin 10, in periodontal disease, 508 Lichen planus, as premalignant lesion, lodine, functions of, 603 84-86 cause and pathogenesis of, 78-79 Iron, importance of, 603 clinical features of, 79-80 requirements for, 604 diagnosis of, and histopathologic Irrigation, supragingival oral, 586 features of, 81-83 epidemiology of, 77 erosive, 80, 81 kK oral, 148 Kaposi's sarcoma, 196-197 plaquelike, 81 reactions in, diseases, drugs and Kawasaki disease, 250 materials implicated in, 85 reticular, 80 treatment of, 83-84 L Laser fluorescence, 745-747 Lichenoid drug reactions, 86 quantitative, 834, 868, 914 lichen planus, and lichenoid mucositis, Al-Khateeb study using, 759-760 77-89 components of system, 756-757 Lichenoid mucositis, lichen planus, and Connersville study using, lichenoid drug reactions, 77-89 760-761 for detection of hidden caries, Lidocaine patch, transdermal, in 765-766 osteoarthritis of temporomandibular for early detection of active joint, 335 caries, 765-766 Life expectancy, 429-430 history of, 756 images illustrating, 759 Lifespan developmental issues, in frail Indiana-lowa validation study of, older adults, 448-449 764-765 in functionally dependent older adults, investigations in, 757-758 449 Osaka study using, 762-764 in functionally independent older software program for, 758 adults, 448 Tranaeus study using, 761~—762 in oral diagnostics, 447-449 Laser fluorescence radiology, and Light, near-infrared. See Near-infrared light. transillumination, 739-752 Light fluorescence, quantitative, for Laser therapy, in oral mucositis, 180 monitoring of caries process, 753-770 Lasers, for tooth preparation, 883-884 Light-induced fluorescence, quantitative, for detection of caries, 800-802 Lentigo, 188 Linea alba buccalis. of labial and buccal Letters, consultative, for care of elderly mucosa, 5 patients, 385, 386, 387 Linear IgA disease, childhood, 248-249 Leukoedema, of labial and buccal mucosa, 3-4 Lipids, role in nutrition, 597 Leukoplakia, 144, 149, 150 Lipoma, 234-235 932 CUMULATIVE INDEX Lipopolysaccharide, from plaque biofilms, Medical care, versus dental care, subsidized, events triggered by, 554 366 Lipopolysaccharide biofilm-associated Medications, frequently prescribed for older bacteria, 495 adults, 414-416 dental management Lipoxins, in periodontal disease, 508 considerations and, 415 Lip(s), commissural lip pits of, 1—2 oral effects of, for treatment of ephelides of, 2 osteoporosis, 474 labial varices of, 2—3 prescribed by dentists, 419-423 problematic or potentially Living wills, 405, 406 inappropriate, for older adults, Long-term care patients, elderly, caring for, 414 future trends in, 438-439 problems related to, avoidance of, oral-health-related concerns 423-424 in, 429-443 factors contributing to, 413 quality of life in, oral health polymedicine and, 412-413 and, 437-438 salivary hypofunction and, 311 frailty and, 430 use of, and prescribing considerations for, in elderly, 411-427 Long-term care staff, 380-381 by older adults, 411-412 Low birth weight, preterm, and periodontal Melanoacanthoma, 195 disease, 542-544 Melanoma(s), oral mucosal, 193-195 Lupus erythematosus, acute cutaneous, 132 Melanoplakia, 187 antiphospholipid syndrome in, 137 Melanosis, 187 cardiovascular disease in, 136 chronic cutaneous, 129-132 Melanotic macules, 188—189 clinical features of, 129 Melanotic neuroectodermal tumor of epidemiology of, 127 infancy, 253 head and neck manifestations of, 137-138 Memory, and aging, 391-392 hematologic disorders in, 137 Microdentistry, concepts of, minimal infection in, 136—137 intervention and, 827-829 manifestations of, and impact on dental care, 130 Minerals, importance of, 601-607 mucocutaneous disease in, 129 major, 602-603 treatment of, 134-135 trace, 603-604 mucosal lesions in, 132—133 ultratrace, 604 neuropsychiatric manifestations of, 135 Miswak, 608 oral manifestations of, 127-141 Molybdenum, 604 pathogenesis of, 127-129 renal disease in, 135 Morsicatio buccarum, of labial and buccal subacute cutaneous, 131 mucosa, 5—6 Lymphangioma, 195, 252-253 Mouth, dry, restorative treatment in, 319-322 Lymphoid tissue, hyperplastic, 11—12 floor of, lingual varicosities of, 12 Mouthrinses, 582-585, 616-617 M Mucocele(s), 191, 224-226 Macrophages, periodontitis and, 505 in children, 242-243 Magnesium, source of, 603 Mucormycosis, 58 Manganese, 604 Mucosa, labial and buccal, fordyce granules of, 4, 5 Measles, in children, 246 leukodema of, 3-4 Medicaid, 366 linea alba buccalis of, 5